Ropes & Gray acted as legal counsel to Vapotherm, Inc. in the transaction. Cooley acted as legal counsel to Perceptive and Latham & Watkins acted as...
Vapotherm’s Merger and Take-Private
Serenity Kids’ $52 Million Series B Funding Round
Haynes and Boone represented Serenity Kids in the transaction, and Latham & Watkins represented Stride Consumer Partners. Serenity Kids, a shelf-stable pouched baby food brand, announced...
PROCEPT BioRobotics’ $172.5 Million Common Stock Offering
Latham & Watkins advised PROCEPT BioRobotics, and Shearman & Sterling advised the underwriters. PROCEPT BioRobotics Corporation announced a follow-on offering of 5,085,494 shares of common stock at...
Indivior’s $145 Million Acquisition of Opiant Pharmaceuticals
Covington & Burling LLP advised Indivior, while Latham & Watkins LLP represented Opiant in the transaction. Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) has entered into a definitive...
Spectrum Pharmaceuticals’ $65 Million Debt Financing Agreement With SLR Capital Partners
Latham & Watkins represented Spectrum Pharmaceuticals in the deal. Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, has entered into...
Procept BioRobotics’ $163.9 Million Initial Public Offering
Latham & Watkins represented PROCEPT in the transaction. PROCEPT BioRobotics Corporation, a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology,...
Eliem Therapeutics’ $80 Million Initial Public Offering
Latham & Watkins represented the underwriters in the offering. Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to...